公开(公告)号：US09796708B2

公开(公告)日：2017-10-24

申请号：US14780018

申请日：2014-03-13

Applicant: AbbVie Inc.

Inventor： Yunsong Tong ,  Milan Bruncko ,  Richard F. Clark ,  Michael Curtin ,  Alan S. Florjancic ,  Robin R. Frey ,  Jianchun Gong ,  Todd M. Hansen ,  Zhiqin Ji ,  Chunqiu Lai ,  Anthony Mastracchio ,  Michael Michaelides ,  Juliem Miyashiro ,  Roberto M. Risi ,  Xiaohong Song ,  Zhi-fu Tao ,  Keith W. Woods ,  Guidong Zhu ,  Thomas Penning ,  Andrew Souers ,  Rajeev Goswami ,  Omprakash Reddy Iguturi ,  Madhu Babu Dabbeeru

IPC: C07D401/02 ,  C07D401/10 ,  A61K31/437 ,  A61K31/4353 ,  C07D471/04 ,  A61K45/06 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/5377

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

公开(公告)号：US20160060257A1

公开(公告)日：2016-03-03

申请号：US14780018

申请日：2014-03-13

Applicant: ABBVIE INC.

Inventor： Yunsong Tong ,  Milan Bruncko ,  Richard F. Clark ,  Michael Curtin ,  Alan S. Florjancic ,  Robin R. Frey ,  Jianchun Gong ,  Todd M. Hansen ,  Zhiqin Ji ,  Chunqiu Lai ,  Anthony Mastracchio ,  Michael Michaelides ,  Juliem Miyashiro ,  Roberto M. Risi ,  Xiaohong Song ,  Zhi-fu Tao ,  Keith W. Woods ,  Guidong Zhu ,  Thomas Penning ,  Andrew Souers ,  Rajeev Goswami ,  Omprakash Reddy Iquturi ,  Madhu Babu Dabbeeru

IPC: C07D471/04 ,  A61K31/5377 ,  A61K31/437 ,  A61K31/4545

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

Abstract translation: 公开了式（IIa）的化合物，其中R1，R2，R3A，R3B，R3C，R3D，R3E和R4如说明书中所定义，及其药学上可接受的盐。 这些化合物可以用作治疗包括癌症在内的疾病的药剂。 还提供了包含一种或多种式（IIa）化合物的药物组合物。

公开(公告)号：US20200010480A1

公开(公告)日：2020-01-09

申请号：US16575114

申请日：2019-09-18

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： Patrick B. Brady ,  Wilfried Braje ,  Yujia Dai ,  George A. Doherty ,  Jane Gong ,  Katja Jantos ,  Cheng Ji ,  Andrew S. Judd ,  Aaron R. Kunzer ,  Chunqiu Lai ,  Anthony Mastracchio ,  Roberto M. Risi ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao ,  Jesse A. Teske ,  Xilu Wang ,  Michael D. Wendt ,  Yiyun Yu ,  Guidong Zhu ,  Thomas D. Penning

IPC: C07D498/18 ,  A61P35/00 ,  C07D519/00 ,  C07D495/18 ,  C07D495/16

Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

公开(公告)号：US20190055264A1

公开(公告)日：2019-02-21

申请号：US15998688

申请日：2018-08-15

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： Patrick B. Brady ,  Wilfried Braje ,  Yujia Dai ,  George A. Doherty ,  Jane Gong ,  Katja Jantos ,  Cheng Ji ,  Andrew S. Judd ,  Aaron R. Kunzer ,  Chunqiu Lai ,  Anthony Mastracchio ,  Roberto M. Risi ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao ,  Jesse A. Teske ,  Xilu Wang ,  Michael D. Wendt ,  Yiyun Yu ,  Guidong Zhu ,  Thomas D. Penning

IPC: C07D498/18 ,  C07D495/18 ,  C07D519/00 ,  A61P35/00

Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).